OncoMatch/Clinical Trials/NCT07403266
Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
Is NCT07403266 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies YCJ-01 Full Spectrum cannbis Extract for tuberous sclerosis complex (tsc).
Treatment: YCJ-01 Full Spectrum cannbis Extract — 1\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Must have received: antiepileptic drug
not responding successfully to traditional AEDs (2 or more)
Must have received: ketogenic diet
not responding successfully to...ketogenic diet
Must have received: vagal nerve stimulator
not responding successfully to...vagal nerve stimulator
Cannot have received: cannabis oil
Patients who have received products with cannabis oil in the last 12 weeks
Lab requirements
Blood counts
platelets < 80000/mm3, white blood cell count <3000/mm3, hematologic dysfunction with values above the normal limits
Kidney function
values above the normal limits of creatinine and urea
Liver function
values 2 times the normal limits of transaminases, increased bilirubin levels more than twice the normal limit, cirrhosis, chronic hepatitis (hepatitis B or C)
Cardiac function
cardiac failure
Cardiac, renal, and hepatic failure, pancreatic insufficiency, or hematologic dysfunction with values above the normal limits of creatinine and urea; values 2 times the normal limits of transaminases, lipases, and serum amylase; platelets < 80000/mm3, and white blood cell count <3000/mm3. Uncontrolled severe medical condition such as: hepatic disease, increased bilirubin levels more than twice the normal limit, cirrhosis, chronic hepatitis (hepatitis B or C), uncontrolled diabetes (defined as blood glucose >150 mg%), (chronic or acute) active infections or uncontrolled severe infections, or active bleeding.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07403266 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cannabis oil disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify